The majority of MDS cases in this patient cohort did not exhibit CLL-1 expression as a reliable marker for differentiating between normal and aberrant CD34 + CD38- cells, as only 17% of the cases presented CLL-1 expression of 10% or higher [11]. This evidence concerns the gene CLEC12A and myelodysplastic syndrome.